BioCryst Pharmaceuticals-BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2024, BioCryst Pharmaceuticals (BCRX) reported revenue of $131.53 million, up 40.8% over the same period last year. EPS came in at -$ 0.13, compared to - $0.28 in the year-ago quarter.The reported revenue represents a surprise of +0.56% over the Zacks Consensus Estimate of$ 130.8 million. With the consensus EPS estimate being -$0.06, the EPS surprise was -116.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...